We are live on ! Find out more
MREO

Mereo BioPharma
MREO

86 hedge funds and large institutions have $268M invested in Mereo BioPharma in 2025 Q2 according to their latest regulatory filings, with 12 funds opening new positions, 31 increasing their positions, 19 reducing their positions, and 16 closing their positions.

New
Increased
Maintained
Reduced
Closed

148% more call options, than puts

Call options by funds: $8.29M | Put options by funds: $3.35M

63% more repeat investments, than reductions

Existing positions increased: 31 | Existing positions reduced: 19

48.13% more ownership

Funds ownership: 13.97% → 62.11% (+48%)

7% more capital invested

Capital invested by funds: $250M → $268M (+$17.5M)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

4% less funds holding

Funds holding: 90 → 86 (-4)

25% less first-time investments, than exits

New positions opened: 12 | Existing positions closed: 16

Holders
86
Holders Change
-4
Holders Change %
-4.44%
% of All Funds
1.13%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.01%
New
12
Increased
31
Reduced
19
Closed
16
Calls
$8.29M
Puts
$3.35M
Net Calls
+$4.95M
Net Calls Change
+$3.19M

Top Buyers

Rank Fund Capital Flow
1
FLSM
Frazier Life Sciences Management
California
+$3.91M
2
Goldman Sachs
Goldman Sachs
New York
+$2.33M
3
Aberdeen Group
Aberdeen Group
United Kingdom
+$2.03M
4
Fidelity Investments
Fidelity Investments
Massachusetts
+$1.74M
5
Citadel Advisors
Citadel Advisors
Florida
+$1.01M

Top Sellers

Rank Fund Capital Flow
1
Janus Henderson Group
Janus Henderson Group
United Kingdom
-$12.2M
2
RSCM
Rock Springs Capital Management
Maryland
-$5.36M
3
Adage Capital Partners
Adage Capital Partners
Massachusetts
-$3.83M
4
UBS AM
UBS AM
Illinois
-$3.53M
5
Morgan Stanley
Morgan Stanley
New York
-$3.36M
Name Holding Trade Value Shares
Change 		Change in
Stake
Janus Henderson Group
1
Janus Henderson Group
United Kingdom
$48.1M -$12.2M -5,046,529 -22%
RCMNY
2
Rubric Capital Management (New York)
New York
$41.5M – – –
FLSM
3
Frazier Life Sciences Management
California
$25.6M +$3.91M +1,620,249 +21%
MP
4
Mangrove Partners
Connecticut
$23.4M – – –
DM
5
Deerfield Management
New York
$18.2M – – –
Alkeon Capital Management
6
Alkeon Capital Management
New York
$12.7M – – –
RSCM
7
Rock Springs Capital Management
Maryland
$12.1M -$5.36M -2,218,955 -33%
6CM
8
683 Capital Management
New York
$11.8M -$688K -285,000 -6%
CC
9
Clearline Capital
New York
$9.81M +$966K +400,269 +12%
Goldman Sachs
10
Goldman Sachs
New York
$8.37M +$2.33M +964,148 +45%
Aberdeen Group
11
Aberdeen Group
United Kingdom
$8.21M +$2.03M +840,518 +38%
TC
12
Tejara Capital
United Kingdom
$6.59M -$219K -90,887 -4%
Renaissance Technologies
13
Renaissance Technologies
New York
$4.01M +$314K +130,000 +10%
Fidelity Investments
14
Fidelity Investments
Massachusetts
$4.01M +$1.74M +719,400 +95%
SSA
15
Schonfeld Strategic Advisors
New York
$2.47M -$1.64M -681,416 -43%
Morgan Stanley
16
Morgan Stanley
New York
$2.13M -$3.36M -1,394,265 -64%
Marshall Wace
17
Marshall Wace
United Kingdom
$2.08M – – –
HP
18
HealthInvest Partners
Sweden
$2.07M +$905K +374,901 +96%
Citadel Advisors
19
Citadel Advisors
Florida
$2.06M +$1.01M +417,006 +121%
Two Sigma Investments
20
Two Sigma Investments
New York
$1.79M +$999K +413,952 +169%
SCM
21
Soleus Capital Management
Connecticut
$1.63M -$211K -87,242 -13%
Millennium Management
22
Millennium Management
New York
$1.61M +$486K +201,242 +51%
AGP
23
Artia Global Partners
Florida
$1.29M +$130K +54,002 +13%
BlackRock
24
BlackRock
New York
$1.23M +$437K +181,004 +66%
Hudson Bay Capital Management
25
Hudson Bay Capital Management
Connecticut
$1.22M – – –
1
2 3 4 5

MREO Hedge Fund Activity: Q2 2025 in Review

86 of the 7,595 institutional investors tracked by Wall St. Rank reported a position in Mereo BioPharma (MREO) for Q2 2025, worth a combined $268M — up 7% from $250M a quarter earlier.

Sellers outnumbered buyers: 16 funds closed out of MREO and 12 opened new positions — a net loss of 4 holders — while 19 trimmed existing stakes and 31 added.

The largest buyer was Frazier Life Sciences Management, adding an estimated $3.91M. The largest seller was Janus Henderson Group, cutting an estimated $12.2M.

  • 86 institutional investors held Mereo BioPharma (MREO) as of Q2 2025, down from 90 in Q1 2025.
  • Funds reported $268M of Mereo BioPharma stock for Q2 2025, up 7% quarter-over-quarter.
  • 12 funds opened new Mereo BioPharma positions in Q2 2025 and 16 closed out, a net change of -4 holders.
  • The largest Mereo BioPharma buyer in Q2 2025 was Frazier Life Sciences Management, an estimated $3.91M added.
  • The largest Mereo BioPharma seller in Q2 2025 was Janus Henderson Group, an estimated $12.2M sold.

Based on aggregated 13F filings for Q2 2025.